Combination Therapy With Curcumin Plus Tamsulosin and Finasteride in the Treatment of Men With Benign Prostatic Hyperplasia

A Single Center, Randomized Control Study

Jing Qiao; Yu Gan; Yuchen Gong; Qingtian Song; Bo Zhang; Bingsheng Li; Feng Ru; Yang Li; Yao He


Transl Androl Urol. 2021;10(8):3432-3439. 

In This Article


Patient Characteristics

The demographic and baseline characteristics of the clinical indicators studied are shown in Table 1. One hundred and twenty-two patients were enrolled in this study, of whom 116 completed the whole procedure (116/122, 95.1%). Six patients withdrew from the survey; of these 4 were in the BSM group (2 patients were lost to follow-up, 1 patient withdrew due to gastrointestinal adverse reactions, 1 patient had prostate surgery due to acute urinary retention), and 2 patients were in the curcumin + BSM group and were lost to follow-up (Figure S1). There were no significant differences in demographic and baseline characteristics between the two groups.

Clinical Evaluations After Treatment

At the end of the 6-month treatment, no statistically significant differences were observed in BMI, WC, and PPFT in the BSM group compared with baseline. In the curcumin + BSM group, there was also no significant difference in BMI compared with baseline, while both WC and PPFT decreased significantly compared to those at baseline (P<0.05). Additionally, there were significant improvements in PV, Qmax, IPSS-total, IPSS-voiding subscore (IPSS-V), IPSS-storage subscore (IPSS-S), and QoL from baseline after treatment in both groups (P<0.05). The IIEF-5 score also decreased slightly in the BSM group but increased moderately in the curcumin + BSM group; however, neither of these changes were statistically significant (Table 2).

No significant difference was observed in BMI, PV, Qmax, IPSS-total and IPSS-V after 6-month treatment in between-group analysis. However, WC and PPFT in the curcumin + BSM group were significantly lower than those in the BSM group (P<0.05). Although IPSS-total and IPSS-V revealed no significant differences between the two groups after treatment, IPSS-S and QoL scores significantly improved the curcumin + BSM group (P<0.05). Interestingly, IIEF-5 in the curcumin + BSM group improved significantly compared with that in the BSM group (P<0.05), suggesting that curcumin may possess a protective effect on erectile function (Table 2).